Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
Read Now: Expert Opinions on HIV Cure Research
  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

Coming, Going and Gone: The Drug Development Pipeline, 2002

March 12, 2002

A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!

Development Terminated
GW420867X/HBY1293GlaxoSmithKlineJAIDS 2000; also summer IAS meeting
ALX40-4CAllelix PharmaceuticalsFormulation difficulties, lack of efficacy
AMD3100AnorMed Inc.Cardiac arrhythmias at high doses, lack of efficacy at low
PD-178390Parke-DavisCasualty of Pfizer merger
CI-1012Parke-DavisCasualty of Pfizer merger
PNU-142721Pharmacia & UpjohnCasualty of P&U’s decision to leave HIV field
NSC 651016Pharmacia & UpjohnCasualty of P&U’s decision to leave HIV field
UC781Biosyn Inc.Being developed as topical microbicide
zintevir/AR-177Antigenics (formerly Aronex)Terminated subsequent to takeover and poor results
Clinical Hold
emtricitabine/FTC/CoviracilTriangle/AbbottSubmission of NDA to be significantly delayed
(-)dOTC/BCH-10618/SPD754Shire Pharmaceuticals PLCDeaths in monkeys
capravirine/S-1153/AG-1549Agouron (Pfizer)Vasculitis in dogs may mean curtains for cap.
mozenavir/DMP-450DuPont (now BMS)Electro-cardiographic abnormalities in animals
Glacial Development
Pentafuside/T-20Trimeris/Roche48-week results released; NDA to be filed 2nd half 2002
T-1249Trimeris/RochePhase I; longer half-life may allow QD dosing
Late Pipeline
emivirine/MKC-442/CoactinonTriangle/AbbottTriangle hopes to file NDA by year end; ICAAC
Middle Pipeline
atazanavir/BMS-232632Bristol-Myers SquibbMoving slowly but deliberately through phase II
tipranavirBoehringer-Ingelheim"Trinity of major obstacles,” paper at summer IAS
VX-175/GW433908Vertex/GlaxoSmithKlineAmprenavir prodrug, PK dose-ranging at 8CROI
SCH-CSchering/PraecisResults of 8-week study presented at 9CROI
PRO 542Progenics PharmaceuticalsPhase II, being studied in combination with T-20
DPC-083DuPont (now BMS)Eyed to hit market in 2003; paper at 7CROI
TMC-125Tibotec/Virco"Amazing potency" unveiled at 9CROI; to file NDA 2004
Deep Pipeline
dADP/amdoxovirTriangle PharmaceuticalsPhase I/II dose ranging study presented at 8CROI
TMC-120Tibotec/VircoPaper at 8CROI
TMC-126Tibotec/VircoPaper at 8CROI
DPC-961, DPC-963DuPont (BMS)Atazanavir may take priority over these
Calanolide-ASarawakMedPaper on this at 7CROI
GPG-NH2Tripep AB/Karolinska InstituteEarly activity in humans not too impressive
SCH-DSchering/PraecisFollow-up compound to SCH-C
UK-427,857PfizerSaid to be moving into Phase I "soon”
DPC-681, DPC-684DuPont (BMS)Phase I studies on-going; paper at 8CROI
AMD-3465, 8445, 8664AnorMedAMD8664 is orally available analogue of AMD3100
TAK-779Takeda PharmaceuticalsBeing studied in combination with T-20
HE2000Hollis-Eden PharmaceuticalsPhase I/II enrolling in U.S.; info from company, other
PRO 140Progenics PharmaceuticalsMoving into Phase I/II; press release
PRO 367Progenics PharmaceuticalsPhase I recently completed
Hu5A8Tanox Biosystems, Inc.Phase I clinical study began 8/1/01
PEHRG214VirionyxPhase I at Boston Deaconess Hospital, 3/01
HIV NCp7Achillion PharmaceuticalsPre-clinical; also in Phase I for HBV
SPD-756Shire Pharmaceuticals PLCFormerly BCH-13520
Fd4C/ACH-126,443Achillion PharmaceuticalsL. Dunkle on this, but will it go the way of other ‘F’ drugs?
5-helixHoward Hughes Medical Inst.Science 2001, 291: 884-888
ADA (azidocarbonamide)HubripharPhase I/II: AIDS 2001, 15:33-45
S1360Shionogi PharmaceuticalsAnimal safety data at 9CROI; Human study underway
TAK-449Takeda PharmaceuticalsCompany officials refused request for information
T-649Trimeris/RocheSimilar to T-1249; paper at 7/01 IAS meeting
BMS-806Bristol-Myers SquibbIn vitro results at 9CROI; Human trial to start later this year
Merck integrase inhibitorMerckPhase I studies to commence March 2002
Merck prime-boost vaccineMerckSafety trials in HIV-negative volunteers currently underway
Missing in Action
L-756,423/MK-944AMerckReportedly moving into Phase II/III; paper at 7CROI
AG-1776/JE-2147Agouron (Pfizer)All appearances suggest this drug is history.
L-708,906, L-731,988MerckHazuda, D.J., et al. Science 287(Jan. 28):646 (also, Science News)
Didox, TrimodoxMolecules for HealthRibonucleotide reductase inhibitors -- circa 1995
AOP-RANTESGryphon SciencesAnimal (mouse) data only, J Virol 5/99, paper as summer IAS
FP-21399Lexigen PharmaceuticalsBruce Dezube again: J Infect Dis 2000 182:607-10
PRO2000Genetics (formerly Procept)Being tested as topical microbicide at Fenway Center
HGTV43Enzo Biochem, Inc.Paper at summer IAS meeting
SJ-3366Samjin Pharmaceuticals Ltd.Paper at 14th Intl. Conf. on Antiviral Research, 4/01

A note from TheBody.com: Since this article was written, the HIV pandemic has changed, as has our understanding of HIV/AIDS and its treatment. As a result, parts of this article may be outdated. Please keep this in mind, and be sure to visit other parts of our site for more recent information!



  
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by Treatment Action Group. It is a part of the publication TAGline.
 
See Also
More on HIV Medications
More on HIV Drugs in Development

Tools
 

Advertisement